Literature DB >> 24779299

Study of genetic variants of 8q21 and 8q24 associated with prostate cancer in Jing-Jin residents in northern China.

Juan Hui, Yong Xu, Kuo Yang, Ming Liu, Dong Wei, Dong Wei, Yaoguang Zhang, Xiao Hong Shi, Fan Yang, Nana Wang, Yurong Zhang, Xin Wang, Siying Liang, Xin Chen, Liang Sun, Xiaoquan Zhu, Ling Zhu, Yige Yang, Lei Tang, Yuhong Zhang, Ze Yang, Jianye Wang.   

Abstract

BACKGROUND: To identify the genetic risk of six genetic variants at 8q21 and 8q24 (including rs1512268, A; rs12543663, C; rs10086908, C; rs1016343, T; rs13252298, A, and rs6983561, C) associated with prostate cancer in Beijing and Tianjin (Jing-jin) area residents in northern China.
METHODS: 574 subjects were enrolled. Blood samples and clinical information were collected from histologically confirmed prostate cancer cases (n = 286) and clinically evaluated matched normal controls (n = 288) from Chinese men in northern China. Six SNPs at 8q21 and 8q24 were genotyped by high-resolution melt and sequencing in subjects. We compared statistical differences between the prevalence of risk genotypes with prostate cancer in cases and controls and analyzed the association between clinical covariates and risk loci in case groups to infer their relationship with aggressive prostate cancer.
RESULTS: Three genotypes of rs10086908, CC (OR = 2.48; 95% CI = 1.02 - 5.98, p = 0.037) rs1016343, TT (OR = 1.64, 95% CI = 1.07 - 2.53, p = 0.023); and rs6983561, CC (OR = 1.91; 95% CI = 1.09 - 3.63, p = 0.044) at 8q24 were identified to be associated with prostate cancer risk in Jing-jin Chinese. The D' values of both two-locus haplotypes (T-A: rs1016343 vs. rs13252298; T-C: rs1016343 vs. rs6983561) were 0.907 and 0.859, respectively, the three-locus haplotype, only TAC constituted by the loci (rs1016343, T; rs13252298, A; rs6983561, C) was also associated with prostate cancer (p = 0.033), revealing rs1016343 vs. rs6983561 with significant differences between cases and controls. According to clinical covariates and odds ratios of risk genotypes relative to non-risk genotypes, rs6983561, CC was associated with age (OR = 2.5; 95% CI = 1.02 - 6.13, p = 0.039), and tumor aggressiveness (OR = 1.15; 95% Cl = 1.06 - 1.23, p = 0.013).
CONCLUSIONS: The loci including rs10086908, rs1016343, and rs6983561 at 8q24 could be associated with prostate cancer in Jing-jin residents in northern China. Our results suggest that these loci could influence susceptibility to prostate cancer in the northern Chinese population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24779299     DOI: 10.7754/clin.lab.2013.130624

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  5 in total

1.  Association between genetic polymorphisms of long non-coding RNA PRNCR1 and prostate cancer risk in a sample of the Iranian population.

Authors:  Hedieh Sattarifard; Mohammad Hashemi; Shekoofeh Hassanzarei; Behzad Narouie; Gholamreza Bahari
Journal:  Mol Clin Oncol       Date:  2017-10-18

2.  Variants on 8q24 and prostate cancer risk in Chinese population: a meta-analysis.

Authors:  Xiao-Qiang Ren; Jian-Guo Zhang; Shi-Yong Xin; Tao Cheng; Liang Li; Wei-Hua Ren
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Association between 8q24 Gene Polymorphisms and the Risk of Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Ran Li; Zhiqiang Qin; Jingyuan Tang; Peng Han; Qianwei Xing; Feng Wang; Shuhui Si; Xiaolu Wu; Min Tang; Wei Wang; Wei Zhang
Journal:  J Cancer       Date:  2017-09-15       Impact factor: 4.207

4.  The HOTAIR, PRNCR1 and POLR2E polymorphisms are associated with cancer risk: a meta-analysis.

Authors:  Haiyan Chu; Yaoyao Chen; Qinbo Yuan; Qiuhan Hua; Xu Zhang; Meilin Wang; Na Tong; Wei Zhang; Jinfei Chen; Zhengdong Zhang
Journal:  Oncotarget       Date:  2017-06-27

Review 5.  PRNCR1: a long non-coding RNA with a pivotal oncogenic role in cancer.

Authors:  Abhishek Bardhan; Anwesha Banerjee; Keya Basu; Dilip Kumar Pal; Amlan Ghosh
Journal:  Hum Genet       Date:  2021-11-02       Impact factor: 4.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.